The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00853645




Registration number
NCT00853645
Ethics application status
Date submitted
27/02/2009
Date registered
2/03/2009
Date last updated
16/02/2017

Titles & IDs
Public title
Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System
Scientific title
Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System
Secondary ID [1] 0 0
DN-11398
Universal Trial Number (UTN)
Trial acronym
Chronic II
Linked study record

Health condition
Health condition(s) or problem(s) studied:
ACC/AHA/HRS Class I and II Indications for ICD Implantation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Subcutaneous Implantable Defibrillator (S-ICD) System

Experimental: S-ICD System - Single-arm with 6 patients implanted with an S-ICD System


Treatment: Devices: Subcutaneous Implantable Defibrillator (S-ICD) System


Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Induced VF conversion efficacy
Timepoint [1] 0 0
30 days

Eligibility
Key inclusion criteria
- replacement of an existing transvenouse ICD system

- ACC/AHA/HRS Class I or II indications for ICD implantation

- Age >= 18 years

- Appropriate pre-operative ECG as measured with a specially developed template
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subjects unable or unwilling to provide informed consent

- Any condition which precludes the subject's ability to comply with the study
requirements

- Remales who are pregnant or lactating and pre-menopausal women who are unwilling to
use adequate birth control for the duration of the study

- Participation in another investigational device trial at any time during the conduct
of the S-ICD system trial without written consent from the sponsor.

- Patients with a serious medical condition and life expectancy of less than one year.

- Patients with documented spontaneous and frequently recurring VT that is reliably
terminated with anti-tachycardia pacing

- Patients with existing epicardial patches or subcutaneous electrodes in the left
thoracic quadrant

- Patients with chronic renal failure, i.e. with a creatinine level of >2.5 mg/dl unless
prescribed drug therapy known to increase creatinine levels in which case the value
should be <= 3mg/dl

Study design
Purpose of the study
Device Feasibility
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Auckland
Country [2] 0 0
New Zealand
State/province [2] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary objective is to evaluate the safety and performance of the implanted S-ICD system. A
maximum of 10 subjects were to be enrolled and followed for one month to collect data on the
safety, efficacy, and performance of the implanted S-ICD system. Additionally, patient
comfort will be assessed as will cosmetic outcome.
Trial website
https://clinicaltrials.gov/show/NCT00853645
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Stephen O'Connor, PhD, Hon FRACP
Address 0 0
Boston Scientific Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications